(34 days)
Not Found
No
The device description outlines a standard clinical chemistry assay based on spectrophotometry, with no mention of AI or ML techniques. The performance studies focus on traditional analytical metrics like correlation, precision, and linearity.
No
The device is an in vitro diagnostic assay used for quantitating albumin in human serum, which aids in the diagnosis and treatment of conditions but does not directly provide therapeutic action.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Albumin BCP measurements are used in the diagnosis and treatment of kidney disease and liver disease." This indicates the device is used for diagnostic purposes.
No
The device description clearly states it is an "in vitro diagnostic assay" and describes a chemical reaction and measurement of absorbance, indicating it is a physical kit or reagent, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is "used for the quantitation of albumin in human serum." This involves testing a sample taken from the human body.
- Device Description: The description clearly states "Albumin BCP is an in vitro diagnostic assay for the quantitative determination of albumin in human serum." It also describes the process of analyzing the sample outside of the body ("in vitro").
- Purpose: The results are used "in the diagnosis and treatment of kidney disease and liver disease," which is a diagnostic purpose.
All of these points align with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Albumin BCP assay is used for the quantitation of albumin in human serum. Albumin BCP measurements are used in the diagnosis and treatment of kidney disease and liver disease.
Product codes
CJW
Device Description
Albumin BCP is an in vitro diagnostic assay for the quantitative determination of albumin in human serum. The Albumin BCP assay is a clinical chemistry assay in which the albumin in the sample binds to bromcresol purple. The absorbance of the complex is measured at 600 nm and is directly proportional to the albumin concentration in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Albumin BCP assay method comparison yielded acceptable correlation with the Boehringer Mannheim BCP assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9855, slope = 0.950, and Y-intercept = 0.198 g/dL. Precision studies were conducted using the Albumin BCP assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 111 is 2.3% and Level 2/Panel 112 is 2.5%. The Albumin BCP assay is linear up to 7.0 g/dL. The limit of quantititation (sensitivity) of the Albumin BCP assay is 0.1 g/dL. These data demonstrate that the performance of the Albumin BCP assay is substantially equivalent to the performance of the Boehringer Mannheim BCP assay on the Hitachi 717 Analyzer.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
correlation coefficient = 0.9855, slope = 0.950, Y-intercept = 0.198 g/dL, total %CV for Level 1/Panel 111 is 2.3%, total %CV for Level 2/Panel 112 is 2.5%, linearity up to 7.0 g/dL, limit of quantititation (sensitivity) is 0.1 g/dL.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1035 Albumin test system.
(a)
Identification. An albumin test system is a device intended to measure the albumin concentration in serum and plasma. Albumin measurements are used in the diagnosis and treatment of numerous diseases involving primarily the liver or kidneys.(b)
Classification. Class II.
0
MAY 27 1998
510(k) Summary
Submitter's Name/Address
Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038 Contact Person Mark Littlefield Section Manager MS 1-8 Regulatory Affairs (972) 518-7861 Fax (972) 753-3367
| Date of Preparation of this Summary: | April 22, 1998 |
|---|---|
| Device Trade or Proprietary Name: | AlbP |
| Device Common/Usual Name or Classification Name: | Albumin BCP |
| Classification Number/Class: | 75CJW/Class II |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: _______________________________________________________________________________________________________________________________________________
Test Description:
Albumin BCP is an in vitro diagnostic assay for the quantitative determination of albumin in human serum. The Albumin BCP assay is a clinical chemistry assay in which the albumin in the sample binds to bromcresol purple. The absorbance of the complex is measured at 600 nm and is directly proportional to the albumin concentration in the sample.
Substantial Equivalence:
The Albumin BCP assay is substantially equivalent to the Boehringer Mannheim® Albumin BCP Assay (K844426) on the Hitachi® 717 Analyzer.
Both assays vield similar Performance Characteristics.
Albumin BCP 510(k) April 22, 1998 Albbcp2E.lwp
Section II Page 1
1
Similarities to Boehringer Mannheim:
- Both assays are in vitro clinical chemistry methods.
- Both assays can be used for the quantitative determination of albumin. .
- Both assays yield similar clinical results. .
Differences to Boehringer Mannheim:
- There is a minor difference in the assay range. .
Intended Use:
The Albumin BCP assay is used for the quantitation of albumin in human serum.
Performance Characteristics:
Comparative performance studies were conducted using the ALCYON™ Analyzer. The Albumin BCP assay method comparison yielded acceptable correlation with the Boehringer Mannheim Albumin BCP assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9855, slope = 0.950, and Y-intercept = 0.198 g/dL. Precision studies were conducted using the Albumin BCP assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 111 is 2.3% and Level 2/Panel 112 is 2.5%. The Albumin BCP assay is linear up to 7.0 g/dL. The limit of quantititation (sensitivity) of the Albumin BCP assay is 0.1 g/dL. These data demonstrate that the performance of the Albumin BCP assay is substantially equivalent to the performance of the Boehringer Mannheim Albumin BCP assay on the Hitachi 717 Analyzer.
Conclusion:
The Albumin BCP assay is substantially equivalent to the Boehringer Mannheim Albumin BCP assay on the Hitachi 717 Analyzer as demonstrated by results obtained in the studies.
Albumin BCP 510(k) April 22, 1998 Albbcp2E.lwp
Section II Page 2
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized symbol resembling a bird or wing-like shape, positioned to the right. Encircling the symbol are the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement. The text is in uppercase and appears to be in a sans-serif font.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 27 1998
Mark Littlefield Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
K981457 Re: AlbP Regulatory Class: II Product Code: CJW Dated: April 22, 1998 Received: April 23, 1998
Dear Mr. Littlefield:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and . . . . . ... prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact. the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Gutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
Albumin BCP__ Device Name: _______________
7
Indications For Use:
The Albumin BCP assay is used for the quantitation of albumin in human serum. Albumin BCP measurements are used in the diagnosis and treatment of kidney disease and liver disease.
(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number k98/457
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801.109) OR
Over-The-Counter Use _________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)